Back to top
more

Health Catalyst (HCAT)

(Delayed Data from NSDQ)

$7.70 USD

7.70
388,823

-0.07 (-0.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $7.64 -0.06 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Health Catalyst (HCAT) Tops Q1 Earnings and Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 225% and 3.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 44.12% and 9.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Does Health Catalyst (HCAT) Have the Potential to Rally 30.43% as Wall Street Analysts Expect?

The consensus price target hints at a 30.4% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Industry Outlook Highlights Inspire Medical Systems, Olink Holding and Health Catalyst

Inspire Medical Systems, Olink Holding and Health Catalyst have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks Countering Industry-wide Headwinds

Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Olink Holding (OLK) and Health Catalyst (HCAT) are expected to gain even as COVID-19 severity fades.

NextGen (NXGN) Riding on the Success of Cloud-Based Solution

NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.

Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Olink Holding AB (publ) Sponsored ADR (OLK) Beats Q4 Earnings and Revenue Estimates

Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 25% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 Medical Info Systems Stocks Braving Industry-wide Headwinds

Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.

Does Health Catalyst (HCAT) Have the Potential to Rally 61% as Wall Street Analysts Expect?

The consensus price target hints at a 61.5% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Health Catalyst (HCAT) Climb 113% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 113% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 35% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Definitive Healthcare Corp. (DH) Surpasses Q3 Earnings and Revenue Estimates

Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 25% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates

RadNet (RDNT) delivered earnings and revenue surprises of -650% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 24.53% and 5.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates

Inspire (INSP) delivered earnings and revenue surprises of 21.79% and 6.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cerner (CERN) Q4 Earnings Top Estimates

Cerner (CERN) delivered earnings and revenue surprises of 5.68% and 2.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 18.18% and 1.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Health Catalyst (HCAT) to Report a Decline in Earnings: What to Look Out for

Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day

Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day